Page 3 - Dr Lal Pathlabs

Major fire in pathology lab building in Delhi's Rohini; nobody injured

A major fire broke out in a pathology laboratory in north Delhi's Rohini late last night, the fire department said on Monday. No one was reported injured. Officials said that the fire broke out on the third and fourth floor of a building which housed the pathology lab. The fire was reported to the department around 12.45 am. "Total 10 fire engines were rushed to the spot immediately. It took more than two hours to douse the flames completely. The fire was near the lift shaft. No one was injured in the fire," an official of the Delhi Fire Service said. The person said that the police have been informed for further investigation into the matter.

Dr Lal PathLabs Q2 results: Profit jumps 54.8%, revenue rises 12.63%

Dr Lal PathLab's share price rose to 3.30 per cent, ending the day's trade at Rs 2,455 apiece on the BSE

Dr Lal Pathlabs Q1FY24 result: Profit up 17% YoY; Rs 6 dividend declared

The total income for Q1FY24 came in at Rs 495.1 crore, compared to Rs 459.3 crore year-on-year

Dr Lal PathLabs reports decline in profit for quarter ending March

Dr. Lal PathLabs Ltd on Thursday reported a sixth consecutive fall in quarterly profit as a continued slide in income from Covid-related testing outpaced growth in its core business

No rerating yet for diagnostic players despite price hikes as margins fall

While discounts have come down, pricing gap still large between incumbents and new players

No rerating yet for diagnostic players despite price hikes as margins fall

While discounts have come down, pricing gap still large between incumbents and new players

Dr Lal PathLabs Q3 net down 7% to Rs 54 cr, revenue declines to Rs 489 cr

Dr Lal PathLabs on Thursday said its consolidated profit after tax declined 7 per cent to Rs 54 crore for the December quarter. The company had reported a net profit of Rs 58 crore in the October-December quarter of the previous fiscal. Revenue also declined to Rs 489 crore for the period under review as compared with Rs 497 crore in the year-ago period, the company said in a regulatory filing. "We continue to focus on geographical expansion and strengthen our presence in Tier 2, Tier 3 towns. Our focus continues to take a higher market share in West and South markets by leveraging technology and promoting high-end super specialty test portfolios," Dr Lal PathLabs Managing Director Om Manchanda said. Shares of the company were trading 1.63 per cent down at Rs 2,019.15 apiece on the BSE.

Pharma, healthcare Q3FY23 preview: Cost pressures abating to aid margins

Hospitals are expected to report a soft Q3 result due to a mix of seasonality and easing pent-up demand, however, average revenue per occupied bed is likely to remain steady

Lal PathLabs targets leadership position in west India in 5 years

Om Manchanda, MD, Dr Lal Pathlabs said that the contribution of the west zone has gone up from 6 percent in FY15 to 8 percent in FY20 and 15 percent in the first half of FY23

Healthcare stocks rally up to 8% as Covid cases spurt in China, Japan

Reports suggest that Union Health Minister Mansukh Mandaviya will review the Covid-19 pandemic situation, in view of a spurt in COVID-19 cases in Japan, South Korea, Brazil, China and the US.

Multiple headwinds could act as margin tourniquet for diagnostics

Competitive pressures, valuations cap gains from current levels

Dr Lal PathLabs Q2 profit slumps on falling Covid income, higher expenses

Indian medical diagnostics firm Dr. Lal PathLabs Ltd on reported a 24.5% drop in September quarter profit as a sustained decline in revenue and volume from its Covid-19 related business

Q2FY23 preview: Modest revenue growth, Ebitda decline seen in pharma cos

While domestic market demand is strong, analysts expect higher raw material and freight costs to affect business in US, other countries; healthy YoY growth seen in hospitals and diagnostics

Dr Lal PathLabs Q1 net profit dips 57% to Rs 58 cr; revenue falls 17%

Diagnostic services provider Dr Lal Path Labs on Thursday said its consolidated net profit declined 57 per cent to Rs 58 crore for the first quarter ended June 30

Covid-19: Analysts dump diagnostic firms for multiplexes on solid outlook

Experts believe the current news cycle may keep the stock prices of related players volatile in the near term, but any fundamental or direct impact, in the long run, remains improbable.

Trading strategies for Thyrocare, Dr Lal Path, Metropolis amid Covid scare

Thyrocare, Dr Lal Path Labs and Metropolis are trading almost 50 per cent below their respective all-time highs, the reversal may see breakout if the key respective levels are sustained

Near-term outlook prescription for diagnostic firms looks fragile

Competitive pressures, high valuations limit upsides for listed lab chains

We aim to test 500,000 patients a day in 5 years: Dr Lal PathLabs CMD

Dr Lal PathLabs is India's largest diagnostic services player by revenue, with 289 laboratories across the country

Dr Lal Pathlabs slips 6%, hits 52-week low post muted Q4 results

In Q4FY22, normalised earnings before interest, taxes, depreciation, and amortization (EBITDA) margins contracted 630 bps to 19.4 per cent from 25.7 per cent in Q4FY21

Dr Lal Pathlabs Q4 consolidated PAT dips 27% to Rs 62 cr, stock sheds 1%

Operating revenue rose 12.7% during the quarter to Rs 485.5 cr; Covid-19 and allied segments added roughly 13.6% to Q4 top line